NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SI
Post# of 137
(Total Views: 170)
Posted On: 11/11/2022 4:02:18 PM
NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. According to the update, the objective of this safety evaluation study, conducted by Experimur (a Frontage Company), is to evaluate the SP-26 compound to establish a maximum tolerated dose. The new drug is intended to treat fibromyalgia, a chronic condition causing widespread musculoskeletal pain accompanied by fatigue, sleep problems and memory issues. “Our team is excited about this milestone in our collaboration with our joint venture partner Zylö Therapeutics, headquartered in South Carolina,” said Silo Pharma CEO Eric Weisblum. “Together we have developed a delivery method for a new ketamine formulation that has shown in pre-clinical studies to hold and distribute the drug in a time-released fashion and reduce neuropathic nerve pain. This IND-enabling study coupled with our existing data brings us another step closer to testing in human patients.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. According to the update, the objective of this safety evaluation study, conducted by Experimur (a Frontage Company), is to evaluate the SP-26 compound to establish a maximum tolerated dose. The new drug is intended to treat fibromyalgia, a chronic condition causing widespread musculoskeletal pain accompanied by fatigue, sleep problems and memory issues. “Our team is excited about this milestone in our collaboration with our joint venture partner Zylö Therapeutics, headquartered in South Carolina,” said Silo Pharma CEO Eric Weisblum. “Together we have developed a delivery method for a new ketamine formulation that has shown in pre-clinical studies to hold and distribute the drug in a time-released fashion and reduce neuropathic nerve pain. This IND-enabling study coupled with our existing data brings us another step closer to testing in human patients.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)